Download presentation
Presentation is loading. Please wait.
Published byPamela Little Modified over 9 years ago
1
Role of Neck Dissection for Differentiated Thyroid CA Joint Hospital Surgical Grand Round NDH Dr. Alex TSANG
2
Background Differentiated Thyroid CA refers to – Papillary thyroid CA – Follicular thyroid CA – Comprises almost 90% of all Thyroid CA
3
Papillary Thyroid CA Papillary thyroid cancers (PTC) =77% of thyroid malignancies Strong propensity for regional nodal involvement. Recent analysis which included > 33,000 patients with PTC, reports a 22% incidence of lymphatic involvement at initial operation
4
Follicular Thyroid CA Follicular thyroid cancers (FTC) less common Lower rate of lymphatic involvement In the same analysis only 2% with lymphatic involvement Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008;144(6):1070–7 [discussion: 1077–8].
5
Risk Factors associated with LN Metastasis Fritze D, Doherty G. Surgical Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer. Otolaryngol Clin N Am 43 (2010) 285–300 >
6
Significance of LN Met If LN Met +ve in initial OT – Locoregional Recurrence rate: higher recurrence of DTC in 19% of patients with initially positive nodes and 2% in node-negative patients Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82(11):3553–62. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162(4):353–6.
7
Significance of LN Met If LN Met +ve in initial OT – Distant Met: higher In a series stratified by tumor size, 0.7% of patients initially T1-T3N0 had distant metastases at diagnosis and 2.9% eventually developed distant spread. For T1- T3N1 patients, 8.5% had systemic involvement at diagnosis, and 15.1% later developed systemic disease. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82(11):3553–62. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162(4):353–6.
8
Significance of LN Met If LN Met +ve in initial OT – Survival: inconclusive Some studies showed no significant impact on survival if LN met +ve Some studies showed worse long term survival (at least 14 years) if LN met +ve So, knowing LN status helps to have more accurate staging which affect patients’ further management and prognosis. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82(11):3553–62. McHenry CR, Rosen IB, Walfish PG. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 1991;162(4):353–6.
9
Cervical Lymphatics Anatomy
10
Cervical lymphadenectomy of one or more lymph node groups Selective Neck Dissection
11
Two subtypes commonly encounter in surgery for DTC: – Lateral neck dissection Level II-V – Central compartment neck dissection Level VI Selective Neck Dissection
12
Neck LN Dissection for DTC DTC PTCFTC LN + LN - Senario 1Senario 2Senario 3Senario 4
13
Neck LN Dissection for DTC DTC PTCFTC LN + LN - Senario 1Senario 2Senario 3Senario 4
14
Neck LN Dissection for PTC Senario 1 – For therapeutic neck dissection – Which type? ALWAYS systemic compartment dissection for the involved compartment over berry-picking procedure Davidson HC, Park BJ, Johnson JT. Papillary thyroid cancer: controversies in the management of neck metastasis. Laryngoscope 2008;118(12):2161–5.
15
Neck LN Dissection for DTC DTC PTCFTC LN + LN - Senario 1Senario 2Senario 3Senario 4
16
Neck LN Dissection for PTC Senario 2 1. Total thyroidectomy and surveillance +/- re- operation if LN recurrence appropriate for small, noninvasive, clinically node- negative PTC Cooper D, Doherty G, Haugen B, et. al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. THYROID Volume 19, Number 11, 2009
17
Neck LN Dissection for DTC Senario 2 2. Total thyroidectomy and prophylactic central compartment LN dissection advanced primary tumors extra-thyroidal extention High risk patient group: male, >45 year old Distant met Cooper D, Doherty G, Haugen B, et. al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. THYROID Volume 19, Number 11, 2009
18
Benefits for prophylactic CCLND unanticipated central metastases in 38% to 45% of patients with PTC prevents compression or invasion of critical aerodigestive and neural structures decreases lymphatic recurrence low levels of thyroglobulin which may facilitate surveillance for recurrent disease
19
Drawback for prophylactic CCLND Uncertain about effect on overall survival Higher potential surgical complications – Significantly higher temporary hypoPTH. – When compare with re-op in recurrence patients vs prophylatic CCLND, significantly more permanent RLN palsy. Fritze D, Doherty G. Surgical Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer. Otolaryngol Clin N Am 43 (2010) 285–300
20
Neck LN Dissection for DTC DTC PTCFTC LN + LN - Senario 1Senario 2Senario 3Senario 4
21
Neck LN Dissection for FTC? Senario 3 – Therapeutic neck dissection is indicated Senario 4 – Not for prophylatics neck LN Dissection – Observation and re-operate if recurrence as FTC had a lower risk of LN met
22
Conclusion PTC – Therapeutic systemic functional compartment dissection if LN met is +ve. – Prophylactic CCLND in high risk group in expert hands. FTC – Therapeutic systemic functional compartment dissection if LN met is +ve. – NOT for prophylatic neck LN dissection.
23
The End Questions?
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.